TP53, β-Catenin and c-myc/N-myc status in embryonal tumours with ependymoblastic rosettes

Neuropathology and Applied Neurobiology

Volumn 37, Issue 4, 2011, Pages 406-413

  Gessi, M ^a   zur Muehlen, A ^a   Lauriola, L ^b   Gardiman, M P ^c   Giangaspero, F ^d,e   Pietsch, T ^a  

^a UNIVERSITY HOSPITAL BONN   (Germany)

^b CATHOLIC UNIVERSITY   (Italy)

^c UNIVERSITY OF PADOVA   (Italy)

^d SAPIENZA UNIVERSITY OF ROME   (Italy)

^e IRCCS NEUROMED   (Italy)

Author keywords

Catenin; C myc N myc; CNS PNET; embryonal tumour with abundant neuropil and true rosettes; ependymoblastoma; TP53

Indexed keywords

BETA CATENIN; GLYCINE; MICRORNA; MICRORNA 520G; UNCLASSIFIED DRUG; VALINE; WNT PROTEIN; CTNNB1 PROTEIN, HUMAN; MYC PROTEIN; MYC PROTEIN, HUMAN; PROTEIN P53; TP53 PROTEIN, HUMAN;

AMINO ACID SUBSTITUTION; ARTICLE; BETA CATENIN GENE; CENTRAL NERVOUS SYSTEM TUMOR; CHILD; CHROMOSOME 19Q; CODON; CONTROLLED STUDY; EMBRYONAL TUMOR WITH ABUNDANT NEUROPIL AND TRUE ROSETTE; EPENDYMOBLASTOMA; EXON; FEMALE; GENE AMPLIFICATION; GENETIC SCREENING; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MALE; MEDULLOBLASTOMA; NEUROBLASTOMA; NEUROECTODERM TUMOR; NEUROPIL; ONCOGENE C MYB; ONCOGENE C MYC; POINT MUTATION; PRIORITY JOURNAL; ROSETTE FORMATION; SINGLE STRAND CONFORMATION POLYMORPHISM; TP53 GENE; BRAIN TUMOR; GENETICS; INFANT; NEOPLASM; PATHOLOGY; PRESCHOOL CHILD; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

C-MYC/N-MYC; CNS-PNET; EMBRYONAL TUMOUR WITH ABUNDANT NEUROPIL AND TRUE ROSETTES; EPENDYMOBLASTOMA; TP53;

AMINO ACIDS; DISPLAY DEVICES; GENES;

TUMORS;

BETA CATENIN; BRAIN NEOPLASMS; CHILD; CHILD, PRESCHOOL; FEMALE; GENE AMPLIFICATION; HUMANS; INFANT; MALE; NEOPLASMS, GERM CELL AND EMBRYONAL; POINT MUTATION; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; PROTO-ONCOGENE PROTEINS C-MYC; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 79959456187     PISSN: 03051846     EISSN: 13652990     Source Type: Journal    
DOI: 10.1111/j.1365-2990.2010.01151.x     Document Type: Article

References (27)

1. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK. WHO Classification of Tumours of the Central Nervous System 4th edn. Lyon: IARC press, 2007; 132-46.
2. Eberhart C, Brat D, Cohen K, Burger PC. Pediatric neuroblastic brain tumors containing abundant neuropil and true rosettes. Pediatr Dev Pathol 2000; 3: 346-52
3. Dunham C, Sugo E, Tobias V, Wills E, Perry A. Embryonal tumor with abundant neuropil and true rosettes (ETANTR): report of a case with prominent neurocytic differentiation. J Neurooncol 2007; 84: 91-8
4. Fuller C, Fouladi M, Gajjar A, Dalton J, Sanford RA, Helton KJ. Chromosome 17 abnormalities in pediatric neuroblastic tumor with abundant neuropil and true rosettes. Am J Clin Pathol 2006; 126: 277-83
5. Buccoliero AM, Castiglione F, Degl'Innocenti DR, Franchi A, Paglierani M, Sanzo M, Cetica V, Giunti L, Sardi I, Genitori L, Taddei GL. Embryonal tumor with abundant neuropil and true rosettes: morphological, immunohistochemical, ultrastructural and molecular study of a case showing features of medulloepithelioma and areas of mesenchymal and epithelial differentiation. Neuropathology 2010; 30: 84-91
6. Gessi M, Giangaspero F, Lauriola L, Gardiman M, Scheithauer BW, Halliday W, Hawkins C, Rosenblum MK, Burger PC, Eberhart CG. Embryonal tumors with abundant neuropil and true rosettes: a distinctive CNS primitive neuroectodermal tumor. Am J Surg Pathol 2009; 33: 211-17
7. Judkins AR, Ellison DW. Ependymoblastoma: dear, damned, distracting diagnosis, farewell! Brain Pathol 2010; 20: 133-39
8. KorshunovA, Remke M, Gessi M, Ryzhova M, Hielscher T, Witt H, Tobias V, Buccoliero AM, Sardi I, Gardiman MP, Bonnin J, Scheithauer B, Kulozik AE, Witt O, Mork S, von Deimling A, Wiestler OD, Giangaspero F, Rosenblum M, Pietsch T, Lichter P, Pfister SM. Focal genomic amplification at 19q13.42 comprises a powerful diagnostic marker for embryonal tumors with ependymoblastic rosettes. Acta Neuropathol 2010; 120: 253-60
9. Rickert C, Hasselblatt M. Cytogenetic features of ependymoblastomas. Acta Neuropathol 2006; 111: 559-62
10. Momota H, Shih AH, Edgar MA, Holland EC. C-Myc and β-Catenin cooperatewith loss of p53 to generatemultiple members of the primitive neuroectodermal tumor family in mice. Oncogene 2008; 27: 4392-401
11. Kraus JA, Bolln C, Wolf HK, Neumann J, Kindermann D, Fimmers R, Forster F, Baumann A, Schlegel U. TP53 alterations and clinical outcome in low grade astrocytomas. Genes Chromosomes Cancer 1994; 10: 143-49
12. Koch A, Waha A, Tonn JC, Sörensen N, Berthold F, Wolter M, Reifenberger J, Hartmann W, Friedl W, Reifenberger G, Wiestler OD, Pietsch T. Somatic mutations of WNT/wingless signaling pathway components in primitive neuroectodermal tumors. Int J Cancer 2001; 93: 445-49
13. Waha A, Watzka M, Koch A, Pietsch T, Przkora R, Peters N, Wiestler OD, von Deimling A. A rapid and sensitive protocol for competitive reverse transcriptase (cRT) PCR analysis of cellular genes. Brain Pathol 1998; 8: 13-18
14. Rutkowski S, von Bueren A, von Hoff K, Hartmann W, Shalaby T, Deinlein F, Warmuth-Metz M, Soerensen N, Emser A, Bode U, Mittler U, Urban C, Benesch M, Kortmann RD, Schlegel PG, Kuehl J, Pietsch T, Grotzer M. Prognostic relevance of clinical and biological risk factors in childhood medulloblastoma: results of patients treated in the prospective multicenter trial HIT'91. Clin Cancer Res 2007; 13: 2651-57
15. Li M, Lee KF, Lu Y, Clarke I, Shih D, Eberhart C, Collins VP, Van Meter T, Picard D, Zhou L, Boutros PC, Modena P, Liang ML, Scherer SW, Bouffet E, Rutka JT, Pomeroy SL, Lau CC, Taylor MD, Gajjar A, Dirks PB, Hawkins CE, Huang A. Frequent amplification of a chr19q13.41 microRNA polycistron in aggressive primitive neuroectodermal brain tumors. Cancer Cell 2009; 16: 533-46
16. BordowSB, Norris MD, Haber PS, Marshall GM, Haber M. Prognostic significance of MYCN oncogene expression in childhood neuroblastoma. J Clin Oncol 1998; 16: 3286-94
17. Warnat P, Oberthuer A, Fischer M, Westermann F, Eils R, Brors B. Cross-study analysis of gene expression data for intermediate neuroblastoma identifies two biological subtypes. BMC Cancer 2007; 7: 89
18. Lamont JM, McManamy CS, Pearson AD, Clifford SC, Ellison DW. Combined histopathological and molecular cytogenetic stratification of medulloblastoma patients. Clin Cancer Res 2004; 10: 5482-93
19. Eberhart CG, Kratz J, Wang Y, Summers K, Stearns D, Cohen K, Dang CV, Burger PC. Histopathological and molecular prognostic markers in medulloblastoma: c-myc, N-myc, TrkC, and anaplasia. J Neuropathol Exp Neurol 2004; 63: 441-49
20. Stearns D, Chaudhry A, Abel TW, Burger PC, Dang CV, Eberhart CG. C-myc overexpression causes anaplasia in medulloblastoma. Cancer Res 2006; 66: 673-81
21. Adesina AM, Nalbantoglu J, Cavenee WK. p53 gene mutation and mdm2 gene amplification are uncommon in medulloblastoma. Cancer Res 1994; 54: 5649-651
22. Kraus JA, Felsberg J, Tonn JC, Reifenberger G, Pietsch T. Molecular genetic analysis of the TP53, PTEN, CDKN2A, EGFR, CDK4 and MDM2 tumour-associated genes in supratentorial primitive neuroectodermal tumours and glioblastomas of childhood. Neuropathol Appl Neurobiol 2002; 28: 325-33
23. Ho YS, Hsieh LL, Chen JS, Chang CN, Lee ST, Chiu LL, Chin TY, Cheng SC. p53 genemutation in cerebral primitive neuroectodermal tumor in Taiwan. Cancer Lett 1996; 104: 103-13
24. Giangaspero F, Eberhart CG, Haapasalo HH, Pietsch T, Wiestler OD, Ellison DW.Medulloblastoma. InWHOClassification of Tumours of the Central Nervous System 4th edn. Eds DN Louis, H Ohgaki, OD Wiestler, WK Cavenee. Lyon: IARC press, 2007; 132-40
25. Eberhart CG, Chaudhry A, Daniel RW, Khaki L, Shah KV, Gravitt PE. Increased p53 immunopositivity in anaplastic medulloblastoma and supratentorial PNET is not caused by JC virus. BMC Cancer 2005; 5: 19
26. Segditsas S, Tomlinson I. Colorectal cancer and genetic alterations in the Wnt pathway. Oncogene 2006; 57: 7531-7
27. Megy S, Bertho G, Gharbi-Benarous J, Baleux F, Benarous R, Girault JP. Solution structure of a peptide derived from the oncogenic protein beta-Catenin in its phosphorylated and nonphosphorylated states. Peptides 2005; 26: 227-41